Overview
PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. We have created a broad and deep pipeline through the expertise of our experienced research and development team and our extensive network of scientists, clinicians and industry leaders.
For Investor Relations inquiries, please contact PureTech's Investor Relations team at: ir@puretechhealth.com.
View our corporate deck.
Share Price
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Half Year Report 2022
Corporate Presentation
Cash at Parent Level
$341.4M PureTech Level Cash and Cash Equivalents as of June 30, 2022 1 with an addition of up to ~$115.4M from the
sale of KRTX shares on August 8, 2022, post-period*
1This represents a non-IFRS measure used by management for planning and reporting purposes. Please see below for a reconciliation of this measure to consolidated cash and cash equivalents, which is the most directly comparable measure calculated in accordance with IFRS:
PureTech Level Cash and Cash Equivalents is defined as cash and cash equivalents held at PureTech Health plc and its wholly-owned subsidiaries only. PureTech Level Cash and Cash Equivalents is an alternative performance measure which is adjusted and constitutes a non-IFRS measure. We believe that these non-IFRS performance measures, when provided in combination with IFRS measures, will provide investors, analysts and other stakeholders with helpful complementary information to better understand our financial position from period to period. The measures are not substitutable for IFRS measures and should not be considered superior to measures presented in accordance with IFRS. These figures are unaudited and do not present all information necessary for an understanding of the Company’s financial condition as of June 30, 2022.
* Presumes the exercise of all call options written by the Company covering 477,100 Karuna shares.